Abstract

The clinical efficacy of nimodipine in the treatment of patients with hypertensive cerebral hemorrhage and its effect on neurological function was explored. The data of hypertensive cerebral hemorrhage patients were analysed, and were randomly divided into observation group and control group each with 59 cases. The control group was given conventional treatment, and the observation group was given intravenous nimodipine. After 14 d of continuous treatment, the clinical treatment effect, National Institutes of Health Stroke Scale score, intracranial hematoma and edema volume, mean arterial pressure, increased intracranial pressure and endothelin-1 levels were observed. Changes in indicators such as Glasgow outcome score and quality of life questionnaire-C30 scores were observed. After treatment, the total effective rate of the observation group was 94.9 %, which was better than that of the control group, 76.3 %. The neurological deficit score, hematoma and edema volume, mean arterial pressure, increased intracranial pressure and endothelin-1 levels of the observation group were significantly improved compared with those before treatment, and were better than the control group where the difference was statistically significant (p<0.05). Similarly, Glasgow outcome score and quality of life questionnaire-C30 scores of the observation group and the control group were both higher after treatment, and comparatively, the observation group was higher than the control group, with a statistical difference p<0.05. Adverse reactions occurred between both the groups were observed and no significant difference was found (p>0.05). Nimodipine treatment for hypertensive cerebral hemorrhage patients can improve the degree of neurological deficit, promote the absorption of cerebral hematoma, reduce intracranial pressure with low adverse reactions and definite clinical effects, and is worthy for application.